We are live on ! Find out more
TEVA icon

Teva Pharmaceutical Industries

508 hedge funds and large institutions have $11.2B invested in Teva Pharmaceutical Industries in 2017 Q4 according to their latest regulatory filings, with 47 funds opening new positions, 129 increasing their positions, 206 reducing their positions, and 125 closing their positions.

New
Increased
Maintained
Reduced
Closed

58% more capital inflows, than outflows

Capital inflows: $2.07B | Capital outflows: $1.31B

44% more funds holding in top 10

Funds holding in top 10: 9 → 13 (+4)

4.89% more ownership

Funds ownership: 48.96% → 53.85% (+4.9%)

5% less funds holding

Funds holding: 536 → 508 (-28)

23% less call options, than puts

Call options by funds: $624M | Put options by funds: $815M

37% less repeat investments, than reductions

Existing positions increased: 129 | Existing positions reduced: 206

62% less first-time investments, than exits

New positions opened: 47 | Existing positions closed: 125

Holders
508
Holders Change
-28
Holders Change %
-5.22%
% of All Funds
11.5%
Holding in Top 10
13
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+44.44%
% of All Funds
0.29%
New
47
Increased
129
Reduced
206
Closed
125
Calls
$624​M
Puts
$815​M
Net Calls
-⁠$191​M
Net Calls Change
+$69.4​M

TEVA Hedge Fund Activity: Q4 2017 in Review

508 of the 4,418 institutional investors tracked by Wall St. Rank reported a position in Teva Pharmaceutical Industries (TEVA) for Q4 2017, worth a combined $11.2B — up 18% from $9.5B a quarter earlier.

Sellers outnumbered buyers: 125 funds closed out of TEVA and 47 opened new positions — a net loss of 78 holders — while 206 trimmed existing stakes and 129 added.

The largest buyer was Capital Research Global Investors, adding an estimated $431M. The largest seller was Bank of New York Mellon, cutting an estimated $193M.

  • 508 institutional investors held Teva Pharmaceutical Industries (TEVA) as of Q4 2017, down from 536 in Q3 2017.
  • Funds reported $11.2B of Teva Pharmaceutical Industries stock for Q4 2017, up 18% quarter-over-quarter.
  • 47 funds opened new Teva Pharmaceutical Industries positions in Q4 2017 and 125 closed out, a net change of -78 holders.
  • The largest Teva Pharmaceutical Industries buyer in Q4 2017 was Capital Research Global Investors, an estimated $431M added.
  • The largest Teva Pharmaceutical Industries seller in Q4 2017 was Bank of New York Mellon, an estimated $193M sold.

Based on aggregated 13F filings for Q4 2017.